Emai:marketing@shtongxi.com.cn
业务咨询专线:400-780-8018
Tel: +1(781)535-1428(U.S. - West Coast)
0044 7790 816 954 (Europe)
Email: marketing@medicilon.com
地址:上海市浦东新区川大路585号
邮编:201299
电话:+86 (21) 5859-1500(总机)
传真:+86 (21) 5859-6369
© 2023 上海pg电子官网生物医药股份有限公司 保留所有权利 沪ICP备10216606号-3
沪公网安备 31011502018888号 | 网站地图
业务咨询
中国:
Email: marketing@shtongxi.com.cn
业务咨询专线:400-780-8018
(仅限服务咨询,其他事宜请拨打川沙总部电话)
川沙总部电话: +86 (21) 5859-1500
海外:
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Overexpression of VEGFR2 can offset the rescue effect of Apatinib on Paclitaxel-induced drug resistance of MGC803 cells. Apatinib inhibits Paclitaxel resistance of MGC803 cells via the VEGFR2 signaling pathway.
In this research, the VEGFR2 sequences were designed and then amplified by RT-PCR. The sequences were then ligated with a pcDNA3.0 plasmid to construct a recombinant pcDNA3.0-VEGFR2 vector (Medicilon).
Reference:
Qian Xie, et al. Apatinib inhibits paclitaxel resistance of gastric carcinoma cells through VEGFR2 pathway. Am J Transl Res. 2022 Jan 15;14(1):421-431. eCollection 2022.